CanadaBis Capital Grant Options

CALGARY, AB / ACCESSWIRE / July 31, 2020 / CanadaBis Capital Inc. (TSXV:CANB) (“CanadaBis” or “the Company”) has granted options to its directors and officers under its Stock Option Plan, to purchase up to 4,550,000 common shares for a period of five years commencing on July31st, 2020 at an exercise price of $0.20 per share. The options will vest one-half immediately and the remaining half shall vest one year from the date of grant.

About CanadaBis Capital Inc.

CanadaBis Capital Inc. (TSXV:CANB) is a vertically integrated Canadian cannabis company focused on achieving large-scale growth in the fast-emerging global cannabis market. By targeting organic growth opportunities alongside the right-fit partners, we remain focused on finding and capitalizing on the changes to grow, diversify and continue to leader our industry.

For more information on CanadaBis Capital, Stigma Grow or Indicative Collection, please visit www.canadabis.com, www.stigmagrow.ca, www.indicativecollection.ca or contact:

Investor Relations
1-888-STI-GMA1
info@stigmagrow.ca

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to our business and operations including development and expansion plans and the timing thereof. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: compliance with extensive government regulation, the general business, economic, competitive, political and social uncertainties; requirement for further capital, delay or failure to receive board, shareholder or regulatory approvals; the results of operations and such other matters as set out in the Filing Statement available on SEDAR at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, readers should not place undue reliance on forward-looking statements. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although we believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on our future results, performance or achievements.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. CanadaBis Capital does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: CanadaBis Capital Inc.

View source version on accesswire.com:
https://www.accesswire.com/599924/CanadaBis-Capital-Grant-Options

Staff

Recent Posts

GaraHerb Supplement Facts, Ingredient Label Details, and Product Disclosures: A 2026 Informational Overview of Male Enhancement Supplement Options

Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…

2 hours ago

Cannabix Technologies announces Non-Brokered LIFE Private Placement

  NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…

2 hours ago

LuminEye Nano-Drops Product Information Updated as Consumer Interest in Eye Health Supplement Options and Vision Support Alternatives Grows in 2026

An informational overview examining category context, publicly available product disclosures, and what consumers often consider…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”)…

2 hours ago

Laughland Teeth Whitening Kit: Ingredients, Disclosures, and What Consumers Are Researching in 2026

A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product…

2 hours ago

The UA Sprinkler Fitters Local 669 JATC – Notice of Privacy Incident

Landover, Maryland, February 6, 2026- The UA Sprinkler Fitters Local 669 Joint Apprenticeship and Training…

11 hours ago